{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:10:35Z","timestamp":1773209435857,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113C-228"],"award-info":[{"award-number":["V113C-228"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03016-8","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T21:02:06Z","timestamp":1723669326000},"page":"1268-1280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in low-weight patients with atrial fibrillation"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-0055","authenticated-orcid":false,"given":"Kuan-Hsuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeh-Yun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chian-Ying","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Lin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Lih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"2","key":"3016_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.chest.2017.10.001","volume":"153","author":"TF Chao","year":"2018","unstructured":"Chao TF et al (2018) Lifetime risks, projected numbers, and adverse outcomes in Asian patients with Atrial Fibrillation: a Report from the Taiwan Nationwide AF Cohort Study. Chest 153(2):453\u2013466","journal-title":"Chest"},{"issue":"07","key":"3016_CR2","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1160\/TH16-11-0876","volume":"117","author":"GYH Lip","year":"2017","unstructured":"Lip GYH et al (2017) Stroke prevention in atrial fibrillation: past, present and future. Thromb Haemost 117(07):1230\u20131239","journal-title":"Thromb Haemost"},{"key":"3016_CR3","doi-asserted-by":"crossref","unstructured":"Hindricks G et al (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J, 2021. 42(5): pp. 373\u2013498","DOI":"10.1093\/eurheartj\/ehaa945"},{"issue":"12","key":"3016_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ et al (2009) Dabigatran versus Warfarin in patients with Atrial Fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"10","key":"3016_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR et al (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"issue":"11","key":"3016_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB et al (2011) Apixaban versus Warfarin in patients with Atrial Fibrillation. N Engl J Med 365(11):981\u2013992","journal-title":"N Engl J Med"},{"issue":"22","key":"3016_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u20132104","journal-title":"N Engl J Med"},{"issue":"7","key":"3016_CR8","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","volume":"44","author":"M Hori","year":"2013","unstructured":"Hori M et al (2013) Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in asians and non-asians with atrial fibrillation. Stroke 44(7):1891\u20131896","journal-title":"Stroke"},{"issue":"6","key":"3016_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","volume":"45","author":"KS Wong","year":"2014","unstructured":"Wong KS et al (2014) Rivaroxaban for stroke prevention in east Asian patients from the ROCKET AF trial. Stroke 45(6):1739\u20131747","journal-title":"Stroke"},{"issue":"3","key":"3016_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","volume":"168","author":"S Goto","year":"2014","unstructured":"Goto S et al (2014) Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for reduction in stroke and other thromboembolic events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J 168(3):303\u2013309","journal-title":"Am Heart J"},{"issue":"4","key":"3016_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1253\/circj.CJ-15-1082","volume":"80","author":"T Yamashita","year":"2016","unstructured":"Yamashita T et al (2016) Edoxaban vs. Warfarin in East Asian patients with Atrial Fibrillation\u3000- An ENGAGE AF-TIMI 48 Subanalysis. Circ J 80(4):860\u2013869","journal-title":"Circ J"},{"issue":"4","key":"3016_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.hrthm.2016.12.036","volume":"14","author":"CS Park","year":"2017","unstructured":"Park CS, Choi EK, Kim HM, Lee SR, Cha MJ, Oh S (2017) Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm 14(4):501\u2013507","journal-title":"Heart Rhythm"},{"issue":"2","key":"3016_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1055\/s-0040-1716540","volume":"121","author":"G Boriani","year":"2021","unstructured":"Boriani G, Ruff CT, Kuder JF et al (2021) Edoxaban versus Warfarin in patients with Atrial Fibrillation at the extremes of Body Weight: an analysis from the ENGAGE AF-TIMI 48 Trial. Thromb Haemost 121(2):140\u2013149","journal-title":"Thromb Haemost"},{"issue":"20","key":"3016_CR14","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIRCULATIONAHA.118.037955","volume":"139","author":"SH Hohnloser","year":"2019","unstructured":"Hohnloser SH et al (2019) Efficacy and safety of Apixaban Versus Warfarin in patients with Atrial Fibrillation and extremes in Body Weight. Circulation 139(20):2292\u20132300","journal-title":"Circulation"},{"issue":"2","key":"3016_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","volume":"13","author":"S Xu","year":"2010","unstructured":"Xu S et al (2010) Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13(2):273\u2013277","journal-title":"Value Health"},{"issue":"28","key":"3016_CR16","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661\u20133679","journal-title":"Stat Med"},{"issue":"25","key":"3016_CR17","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083\u20133107","journal-title":"Stat Med"},{"issue":"1","key":"3016_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jtcvs.2015.03.057","volume":"150","author":"TL McMurry","year":"2015","unstructured":"McMurry TL et al (2015) Propensity scores: methods, considerations, and applications in the Journal of thoracic and Cardiovascular surgery. J Thorac Cardiovasc Surg 150(1):14\u201319","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"18","key":"3016_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","volume":"383","author":"K Okumura","year":"2020","unstructured":"Okumura K et al (2020) Low-dose Edoxaban in very Elderly patients with Atrial Fibrillation. N Engl J Med 383(18):1735\u20131745","journal-title":"N Engl J Med"},{"issue":"10","key":"3016_CR20","first-page":"612","volume":"17","author":"R Krittayaphong","year":"2020","unstructured":"Krittayaphong R et al (2020) Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. J Geriatr Cardiol 17(10):612\u2013620","journal-title":"J Geriatr Cardiol"},{"issue":"9","key":"3016_CR21","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.amjcard.2017.07.050","volume":"120","author":"T Liu","year":"2017","unstructured":"Liu T et al (2017) Meta-analysis of efficacy and Safety of Low-Intensity Warfarin Therapy for east Asian patients with Nonvalvular Atrial Fibrillation. Am J Cardiol 120(9):1562\u20131567","journal-title":"Am J Cardiol"},{"issue":"1","key":"3016_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/europace\/eut263","volume":"16","author":"P Kirchhof","year":"2014","unstructured":"Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL (2014) Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2013European Registry in Atrial Fibrillation (PREFER in AF). Europace 16(1):6\u201314","journal-title":"Europace"},{"issue":"3","key":"3016_CR23","doi-asserted-by":"publisher","first-page":"e005894","DOI":"10.1161\/CIRCOUTCOMES.119.005894","volume":"13","author":"SR Lee","year":"2020","unstructured":"Lee SR et al (2020) Effectiveness and safety of direct oral anticoagulants in relation to temporal changes in their use. Circ Cardiovasc Qual Outcomes 13(3):e005894","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"3016_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1253\/circj.CJ-22-0023","volume":"86","author":"M Akao","year":"2022","unstructured":"Akao M et al (2022) 10-Year trends of Antithrombotic Therapy Status and outcomes in Japanese Atrial Fibrillation patients\u3000- the Fushimi AF Registry. Circ J 86(4):726\u2013736","journal-title":"Circ J"},{"issue":"1","key":"3016_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jcpt.13538","volume":"47","author":"X Gong","year":"2022","unstructured":"Gong X et al (2022) A drug utilization study of oral anticoagulants in five representative cities of China between 2015 and 2019. J Clin Pharm Ther 47(1):38\u201345","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"3016_CR26","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.7326\/M22-0511","volume":"175","author":"WCY Lau","year":"2022","unstructured":"Lau WCY et al (2022) Comparative effectiveness and safety between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban among patients with Atrial Fibrillation: a multinational Population-based Cohort Study. Ann Intern Med 175(11):1515\u20131524","journal-title":"Ann Intern Med"},{"issue":"2","key":"3016_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/ehjqcco\/qcab025","volume":"8","author":"T Yamashita","year":"2022","unstructured":"Yamashita T et al (2022) Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the all Nippon AF in the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes 8(2):202\u2013213","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"5","key":"3016_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH et al (2018) Antithrombotic therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 154(5):1121\u20131201","journal-title":"Chest"},{"key":"3016_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijcard.2016.11.277","volume":"228","author":"CH Lee","year":"2017","unstructured":"Lee CH et al (2017) Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. Int J Cardiol 228:771\u2013778","journal-title":"Int J Cardiol"},{"issue":"3","key":"3016_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3390\/ijerph19031436","volume":"19","author":"S Rogula","year":"2022","unstructured":"Rogula S, G\u0105secka A, Mazurek T, Navarese EP, Szarpak \u0141, Filipiak KJ (2022) Safety and Efficacy of DOACs in patients with Advanced and End-Stage Renal Disease. Int J Environ Res Public Health 19(3):1436","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"3016_CR31","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2018.11.051","volume":"73","author":"SR Lee","year":"2019","unstructured":"Lee SR et al (2019) Direct oral anticoagulants in patients with Nonvalvular Atrial Fibrillation and Low Body Weight. J Am Coll Cardiol 73(8):919\u2013931","journal-title":"J Am Coll Cardiol"},{"key":"3016_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/CLEP.S358277","volume":"14","author":"K Kubota","year":"2022","unstructured":"Kubota K, Ooba N (2022) Effectiveness and safety of reduced and Standard Daily Doses of Direct Oral Anticoagulants in patients with Nonvalvular Atrial Fibrillation: a Cohort Study using National Database representing the Japanese Population. Clin Epidemiol 14:623\u2013639","journal-title":"Clin Epidemiol"},{"issue":"3","key":"3016_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","volume":"156","author":"YH Chan","year":"2019","unstructured":"Chan YH et al (2019) Effectiveness and safety of four direct oral anticoagulants in Asian patients with Nonvalvular Atrial Fibrillation. Chest 156(3):529\u2013543","journal-title":"Chest"},{"issue":"12","key":"3016_CR34","doi-asserted-by":"publisher","first-page":"e014177","DOI":"10.1161\/JAHA.119.014177","volume":"9","author":"HT Yu","year":"2020","unstructured":"Yu HT et al (2020) Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with Atrial Fibrillation. J Am Heart Assoc 9(12):e014177","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03016-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03016-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03016-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T13:08:00Z","timestamp":1729602480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03016-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3016"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03016-8","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"27 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations of conflicts of interest"}}]}}